A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD
NCT03062579
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Neuromyelitis Optica Spectrum Disorders
Neuromyelitis Optica
Devic's Disease
Interventions
DRUG:
Tocilizumab
Sponsor
Fu-Dong Shi